GenVec president and ceo to retire

US firm hires recruitment firm to find a successor

GenVec, a US biopharmaceutical company that uses differentiated, proprietary technologies to create therapeutics and vaccines, says Paul Fischer plans to retire as president and chief executive. Dr Fischer will continue in the role until a successor is named and the ceo transition is complete. The Board will use Spencer Stuart, an executive search firm, to advise it on potential candidates.

Fischer has been with the Gathersburg, MD firm for 15 years.

You may also like

Media
Touchlight wins CPHI Pharma Award for cell-free DNA manufacturing

Touchlight wins CPHI Pharma Award for cell-free DNA manufacturing

The UK biotech's Doggybone DNA platform won the Innovation Catalyst category at CPHI Milan 2026, recognising its potential to support scalable DNA production for genetic medicines
Manufacturing
Xelia and Hisun sign strategic global multiple-API partnership

Xelia and Hisun sign strategic global multiple-API partnership

Long-standing joint venture partners expand collaboration, moving beyond anti-infective APIs into diversified therapeutic areas, including cardiovascular and oncology
Design & Build
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics

The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Finance
Piramal Pharma receives Ontario investment for API site

Piramal Pharma receives Ontario investment for API site

Piramal Pharma Solutions (PPS) is to invest more than $5.3m in upgrading its drug substance manufacturing site in Aurora, Canada, supported by a $1.75m investment from the Ontario government
Manufacturing
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month

Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
Research & Development
Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

Quotient Sciences and Acesion Pharma collaborate on AI-enhanced formulation development

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments
Pharmaceutical
Biosynth expands complex chemistry portfolio for biologics and vaccines

Biosynth expands complex chemistry portfolio for biologics and vaccines

The expansion includes new fluorinated sugars and GMP-grade Poly(I:C), supporting glycoengineering, bioproduction, vaccine and immunotherapy development
Subscribe now